Shrinks In Sneakers

Tag: psychology

  • Narcissistic Personality Disorder: Two Faces Explained

    Narcissistic Personality Disorder: Two Faces Explained

    The key difference between vulnerable narcissistic personality disorder (NPD) and grandiose NPD lies in how the narcissistic traits are expressed and how the person copes with feelings of inadequacy and low self-esteem. Both fall under the umbrella of narcissistic personality disorder, but they represent different presentations:

    Grandiose Narcissism

    • Core Traits:
      • Overt self-importance and entitlement.
      • A strong sense of superiority and belief in their own greatness.
      • Craving admiration and validation from others.
      • Often charismatic, confident, and socially dominant.
    • Defense Mechanisms:
      • Rely on denial and externalizing blame to avoid feeling vulnerable.
      • Tend to dismiss or belittle others’ opinions if they conflict with their own.
    • Interpersonal Behavior:
      • Exploitative in relationships, using others to bolster their self-esteem.
      • Seek out positions of power or visibility to maintain their inflated self-image.
    • Emotional Regulation:
      • Typically outwardly composed and unbothered, though they may become aggressive or vindictive if their self-image is challenged.

    Vulnerable Narcissism

    • Core Traits:
      • Feelings of inadequacy, hypersensitivity to criticism, and low self-esteem.
      • A covert sense of entitlement—believing they deserve admiration but fearing they won’t get it.
      • A façade of humility or introversion, masking deep insecurities.
    • Defense Mechanisms:
      • Use avoidance and withdrawal to protect themselves from perceived rejection or failure.
      • Internalize blame and self-doubt, leading to cycles of shame and self-criticism.
    • Interpersonal Behavior:
      • Appear shy, reserved, or socially anxious, but they harbor fantasies of being special or recognized.
      • May oscillate between needing reassurance and distancing themselves from others out of fear of being hurt.
    • Emotional Regulation:
      • Prone to depression, anxiety, and mood swings.
      • Vulnerable to feelings of emptiness and envy of others’ success.

    Clinical Distinction

    • While grandiose narcissists may seem outwardly self-assured and dominant, vulnerable narcissists are more likely to present with symptoms resembling mood or anxiety disorders, often masking their narcissistic traits.
    • Both types share a fragile self-esteem at their core but manifest it in opposite ways: grandiose types inflate their self-image, while vulnerable types retreat into themselves.

    Grandiose Narcissism in a Clinical Setting

    Case Example:

    • Presentation: A 45-year-old CEO attends therapy after his spouse threatens divorce, citing his arrogance and lack of empathy. He describes the problem as “Everyone just misunderstands how hard it is to be as driven and successful as me.”
    • Behavior in Session:
      • Dominates conversations, dismisses the therapist’s insights, and subtly challenges their expertise.
      • Boasts about his achievements, financial success, and social status but avoids discussing emotional issues or personal failures.
      • Minimizes his spouse’s complaints as “overreactions,” viewing them as jealous or ungrateful.
    • Underlying Issues:
      • Although he appears self-confident, his grandiosity masks deep fears of failure and inadequacy.
      • His need for admiration and his inability to tolerate criticism create interpersonal conflict.
    • Therapeutic Challenge:
      • Establishing rapport while gently confronting his defensiveness.
      • Helping him acknowledge and address the vulnerability underlying his grandiosity without triggering a withdrawal or rage response.

    Vulnerable Narcissism in a Clinical Setting

    Case Example:

    • Presentation: A 30-year-old graduate student seeks therapy for persistent depression and social anxiety. She describes herself as “a failure” and avoids academic conferences because she feels “everyone there is smarter and more talented.”
    • Behavior in Session:
      • Initially shy and reserved but gradually reveals fantasies of being recognized as brilliant and exceptional in her field.
      • Complains about colleagues receiving awards, feeling envious and deeply resentful, but also guilty for having those feelings.
      • Struggles to accept praise, dismissing it as insincere or undeserved, and reacts strongly to perceived slights or criticism.
    • Underlying Issues:
      • She feels torn between craving recognition and fearing rejection.
      • Her self-esteem depends heavily on external validation, but she avoids situations where she might fail or be criticized.
    • Therapeutic Challenge:
      • Helping her tolerate and process feelings of inadequacy without retreating into shame or avoidance.
      • Building her sense of self-worth independent of external achievements or comparisons.

    Comparison:

    1. Interpersonal Dynamics:
      • Grandiose narcissists demand validation and admiration from others; vulnerable narcissists fear and avoid situations where their insecurities might be exposed.
      • The CEO pressures the therapist to affirm his greatness, while the student fears the therapist will see her as inadequate.
    2. Emotional Reactions:
      • The CEO might react to confrontation with anger or dismissal, while the student might respond with shame or withdrawal.
    3. Defense Mechanisms:
      • Grandiose types externalize blame (“They’re the problem”), whereas vulnerable types internalize it (“I’m the problem”).

    Clinical Insights

    Both types present challenges in therapy:

    • Grandiose narcissists may struggle with self-reflection, requiring careful, non-confrontational approaches to expose vulnerabilities.
    • Vulnerable narcissists are often more willing to explore their insecurities but may require help managing their intense shame and self-doubt.

  • Family Ties That Bind: When High Expressed Emotion Worsens Schizophrenia

    Family Ties That Bind: When High Expressed Emotion Worsens Schizophrenia

    In psychiatry we are always asking patients about social support. The presence or absence of social support can have a major impact on treatment response and ability to remain well once someone leaves the hospital. This usually includes support from family members and friends. 

    In 1956 the Medical Research Council Social Psychiatry (MRCSP) London conducted a study regarding the readmission of schizophrenic patients. The research revealed that patients who were stabilized symptomatically and functionally inpatient and subsequently discharged to live with their parents or wives were frequently readmitted for relapse of symptoms compared to those who were discharged to a sibling, or non-family environment. While family involvement is generally a protective factor that helps prevent things like suicide, there are some situations where the over involvement of family can complicate matters and even create worse outcomes.

    This usually occurs when a family has high expressed emotion. 

    Expressed emotion (EE) has consistently been shown to predict relapse in schizophrenia as well as other psychiatric disorders. Expressed emotion is a measure of the family environment that is based on how the relatives of a psychiatric patient spontaneously talk about the patient. 

    It measures 3 aspects of the family environment associated with high expressed emotion:

    1. Hostility (outward anger and frustration towards the patient because the family believes they are choosing to not get better) 
    2. Emotional over-involvement (This is where the family tries to solve all the problems for the patient taking away their ability to be self-reliant). 
    3. Critical comments (where the family views the mentally ill patient as lazy or selfish, not appreciating the difficulty of living with mental illness). 

    However, research has shown the following as indications of an environment with low expressed emotion: 

    1.    Positivity: (statements that express appreciation or support for the patient’s behavior and gives verbal and nonverbal reinforcement). 

    2.    Warmth: (kindness, concern and empathy expressed by the caregiver).

    There is such a thing as too much involvement on the part of the families which can lead to complicating family dynamics and exacerbation of an individual’s symptoms of mental illness. Interventions for improving outcomes include reducing contact with high EE caregivers and providing psychoeducation about EE to care givers. Bringing awareness to this behavior may help family members change. 

  • Breaking the Cycle: Effective Strategies to Prevent Self-Injurious Behavior (SIB)

    Breaking the Cycle: Effective Strategies to Prevent Self-Injurious Behavior (SIB)

    This post comes from another real-world case that I frequently encounter in clinical practice. Self-injurious behavior (SIB) is common in the inpatient care setting and the strategies to prevent it are mostly behavioral. Many patients and families are also looking for pharmacological options. Here are some of the more common options and recommendations for treating SIB.

    Behavioral Interventions

    1. Functional Behavior Analysis (FBA): Start with an FBA to understand why the self-injury is occurring (e.g., to gain attention, avoid demands, or self-soothe). This guides intervention planning.
    2. Positive Reinforcement and Skill Building: Reinforce alternative, adaptive behaviors that fulfill the same needs as self-injury, such as communication skills (e.g., teaching to request attention) or self-soothing techniques.
    3. Cognitive Behavioral Therapy (CBT): For individuals able to engage in talk therapy, CBT can address underlying thoughts and emotions driving SIB, such as distress intolerance, perfectionism, or negative self-beliefs.
    4. Dialectical Behavior Therapy (DBT): DBT is particularly effective for reducing SIB, especially in borderline personality disorder. It combines emotional regulation, mindfulness, and distress tolerance skills.
    5. Environmental Modifications: Minimizing triggers in the individual’s environment can help reduce occurrences. This might include changes in routines, avoiding overstimulation, or modifying demands.
    6. Applied Behavior Analysis (ABA): Techniques from ABA, like differential reinforcement of other behaviors (DRO) or non-contingent reinforcement (NCR), can reduce self-injury by decreasing its functional value.

    Pharmacological Interventions

    1. SSRIs (Selective Serotonin Reuptake Inhibitors): Useful if self-injury is driven by anxiety, depression, or obsessive-compulsive tendencies. SSRIs can help stabilize mood and reduce anxiety, lessening the need for SIB.
    2. Antipsychotics: Atypical antipsychotics, such as risperidone or aripiprazole, are sometimes effective, particularly in autism spectrum disorders or severe intellectual disabilities. However, weigh these benefits against side effects, especially for long-term use.
    3. Mood Stabilizers: Medications like lithium, lamotrigine, or valproate can help regulate mood fluctuations that contribute to SIB. Lithium, in particular, has shown effectiveness in reducing aggression and impulsivity.
    4. Naltrexone: This opioid antagonist can be effective in cases where SIB is hypothesized to release endogenous opioids, providing a calming effect.
    5. Beta-blockers (e.g., propranolol): In cases of high impulsivity or aggression linked to SIB, beta-blockers can reduce physiological arousal, lessening the drive for self-injury.
    6. Clonidine or Guanfacine: These medications, which target the noradrenergic system, can help reduce impulsivity and aggression in patients with ADHD or autism, indirectly lowering self-injury.

    Choosing the best approach depends on the individual’s specific triggers, co-occurring conditions, and underlying motivations for SIB. Integrating both behavioral and medication interventions, while monitoring closely for effectiveness and side effects, often yields the best outcomes.

  • ADHD and Cannabis Use Disorder: Key Facts You Shouldn’t Ignore

    ADHD and Cannabis Use Disorder: Key Facts You Shouldn’t Ignore

    1. Prevalence and Patterns of Use

    People with ADHD have been shown to use cannabis at higher rates than those without ADHD. Studies indicate that adolescents and adults with ADHD are more likely to use cannabis, and they may start using it at a younger age. This may be due to self-medication attempts, as people with ADHD often report using cannabis to help with symptoms like impulsivity, anxiety, and sleep difficulties which seems like a bad idea to me but lets look at the reasons.

    2. Cannabis as a Self-Medication Attempt

    Some people with ADHD use cannabis in an attempt to self-manage their symptoms. Anecdotally, users report feeling more focused, relaxed, and less anxious, though the scientific evidence on cannabis’s effectiveness for ADHD symptom management is not robust. Studies show that while some ADHD symptoms like restlessness might feel alleviated short-term, long-term outcomes often do not show sustained benefit, and impairment can increase over time.

    3. Impact on ADHD Symptoms

    Research on cannabis’s effect on ADHD symptoms is mixed:

    • Impulsivity and Attention: Cannabis can impair attention, memory, and executive functioning, which are already areas of struggle for individuals with ADHD. Heavy cannabis use is associated with poorer performance on tasks measuring these cognitive domains.
    • Cognitive Function: Longitudinal studies have shown that chronic cannabis use can worsen cognitive functions over time, especially if use begins in adolescence. These cognitive impacts may compound ADHD-related deficits.
    • Motivation and Goal-Directed Behavior: Cannabis can affect motivation and goal-directed behavior, which can exacerbate some ADHD symptoms, particularly in individuals who already struggle with organization and task completion.

    4. ADHD as a Risk Factor for Cannabis Use Disorder

    Studies suggest that people with ADHD may be more prone to developing cannabis use disorder (CUD) compared to the general population. Traits like impulsivity and sensation-seeking, common in ADHD, may increase vulnerability to addiction. Additionally, the reinforcing effects of cannabis (e.g., reduction in perceived anxiety) may lead to increased use and dependency in those with ADHD.

    5. Genetic and Neurobiological Factors

    There is some evidence suggesting that the overlap between cannabis use and ADHD may have a genetic or neurobiological basis:

    • Genetic Overlap: Studies have found that genes linked to ADHD, particularly those affecting dopamine function, are also implicated in substance use disorders, including cannabis use disorder.
    • Endocannabinoid System: ADHD and cannabis use affect dopamine and endocannabinoid systems. Some research posits that dysregulation in these systems might underlie both the propensity for ADHD and substance use, but this remains an area for further research.

    6. Cannabis and Medication Interactions

    For those with ADHD taking stimulant medications, cannabis use can interfere with treatment. THC, the psychoactive component of cannabis, can interact with medications like methylphenidate or amphetamine-based treatments, potentially reducing their effectiveness or exacerbating side effects like anxiety and heart palpitations.

    7. Longitudinal and Population Studies

    Long-term studies generally show that early and heavy cannabis use is associated with worse outcomes for individuals with ADHD. These include lower academic achievement, increased rates of unemployment, and higher incidences of mental health issues, especially when cannabis use starts in adolescence.

    Summary

    While some people with ADHD report short-term symptom relief with cannabis, research shows that heavy, frequent use tends to worsen cognitive deficits associated with ADHD over time. Additionally, ADHD may predispose individuals to higher rates of cannabis use and a greater risk of developing cannabis use disorder. While cannabis might seem beneficial for symptom relief in the short term, its long-term use is generally not supported as an effective management strategy for ADHD.

  • Split or Stick? The Real Impact of Dividing Clozapine Doses

    Split or Stick? The Real Impact of Dividing Clozapine Doses

    This post comes from a recent discussion I had with my resident about the utility of splitting clozapine doses in a recent case we had.

    The evidence on splitting clozapine into multiple daily doses primarily stems from clinical observations and smaller studies rather than extensive, randomized controlled trials (RCTs). Since clozapine has a unique pharmacodynamic and pharmacokinetic profile, standardizing an RCT on dose splitting has been challenging.

    1. Clozapine’s Half-Life and Steady-State Concentration: Clozapine has a long half-life (averaging about 12 hours), meaning steady-state concentrations can be reached without strict multiple dosing. Many patients maintain stable blood levels with once-daily dosing, especially at lower doses.
    2. Dose Splitting and Side Effects: Some smaller studies and clinical observations suggest that splitting doses can help reduce peak plasma levels of clozapine, which can be associated with side effects like sedation, hypotension, and dizziness. In these cases, a split dosing regimen may improve tolerability, particularly in patients who experience significant sedation or orthostatic hypotension with a single daily dose.
    3. Metabolic Side Effects and Compliance: In cases where metabolic side effects are of concern, or in patients who may not tolerate high single doses well, dividing doses could help with tolerability, potentially improving compliance and minimizing adverse effects like sedation or metabolic impact.
    4. Seizure Risk: High plasma peaks with a single large dose may theoretically increase the risk of seizures, especially in patients on higher doses of clozapine. Dividing doses is sometimes recommended as a preventive measure to maintain a more consistent blood level, although robust RCT data supporting this specific benefit is lacking.

    While RCT evidence specifically on clozapine dose-splitting remains limited, clinical judgment, patient tolerance, and monitoring of therapeutic blood levels play essential roles in tailoring dose regimens.

  • MAOIs: Mechanism of Action, Common Medications, and Side Effects

    MAOIs: Mechanism of Action, Common Medications, and Side Effects

    Mechanism of Action

    Monoamine oxidase inhibitors (MAOIs) are a class of medications primarily used to treat depression. They work by inhibiting the activity of monoamine oxidase enzymes (MAO-A and MAO-B). These enzymes are responsible for breaking down neurotransmitters such as serotonin, norepinephrine, and dopamine in the brain. By inhibiting these enzymes, MAOIs increase the levels of these neurotransmitters, which can help improve mood and alleviate depressive symptoms.

    Common Medications

    1. Phenelzine (Nardil)
    2. Tranylcypromine (Parnate)
    3. Isocarboxazid (Marplan)
    4. Selegiline (Emsam) – Available as a transdermal patch

    Side Effects

    MAOIs can have significant side effects and interactions, which is why they are often not the first choice for treating depression. Some common side effects include:

    1. Hypertensive Crisis: Consuming foods high in tyramine (such as aged cheeses, cured meats, and fermented products) can cause dangerously high blood pressure.
    2. Orthostatic Hypotension: A sudden drop in blood pressure when standing up, leading to dizziness or fainting.
    3. Insomnia: Difficulty falling or staying asleep.
    4. Weight Gain: An increase in body weight over time.
    5. Sexual Dysfunction: Decreased libido, erectile dysfunction, or difficulty achieving orgasm.
    6. Headaches: Frequent or severe headaches.
    7. Edema: Swelling, particularly in the lower limbs.
    8. Fatigue: General feeling of tiredness or lack of energy.
    9. Dry Mouth: Reduced saliva production, leading to a dry sensation in the mouth.

    Precautions

    • Dietary Restrictions: Due to the risk of hypertensive crisis, patients on MAOIs must follow strict dietary restrictions to avoid tyramine-rich foods.
    • Drug Interactions: MAOIs can interact with numerous medications, including over-the-counter drugs, other antidepressants, and certain pain medications, potentially leading to severe or life-threatening conditions.
    • Medical Monitoring: Regular monitoring by a healthcare professional is essential to manage and mitigate potential side effects and interactions.

    MAOIs can be effective for certain patients, particularly those who have not responded to other antidepressant treatments. However, their use requires careful management due to their side effect profile and interaction potential.

  • Non-Harvard Trained: Real Care, Real Results

    Non-Harvard Trained: Real Care, Real Results

    I constantly come across the phrase “Harvard-trained” in people’s bios. Sure, it brings instant brand recognition and credibility. But in reality, being trained at a prestigious institution—even one like Harvard—doesn’t automatically mean better skills or superior patient care.

    In psychiatry, quality care is shaped by much more than where someone trained. It comes from clinical experience, empathy, lifelong learning, and the ability to genuinely connect with patients. These are the factors that truly define the impact we make.

    While training is important, the real measure of a psychiatrist’s ability is in the care they provide and the outcomes they achieve. Psychiatry is such a nuanced field that no amount of prestige can substitute for hands-on experience and genuine compassion.

    It’s unfortunate that where someone trained is often used as a superficial marker of competence, overshadowing the true work that goes into patient care. Personally, I’d reject a Harvard offer, because for me, it’s about one thing: providing the highest level of care possible, every single day.

  • The more I learn the less certain I am About Things

    The more I learn the less certain I am About Things

    Did you ever feel like the more you learn the less certain you are about things?

    It’s completely natural to feel this way, especially in a field as complex and evolving as psychiatry. Uncertainty and skepticism can be strengths, driving you to seek deeper understanding and remain open to new perspectives and evidence. Here are a few thoughts that might resonate

    Complexity of Human Mind: The human brain and psyche are incredibly complex, and our understanding is still in its infancy. This complexity can make definitive answers elusive.

    Evolving Science: Psychiatry, like all medical fields, is constantly evolving. New research can change our understanding of mental health conditions and treatments, making certainty difficult.

    Individual Differences: What works for one person might not work for another. This variability can make it hard to be sure about diagnoses and treatments.

    Holistic Approach: Embracing uncertainty can lead to a more holistic approach, considering biological, psychological, and social factors in diagnosis and treatment.

    Continuous Learning: Your skepticism can fuel a commitment to continuous learning and improvement, which is essential in providing the best care.

    Collaboration and Discussion: Engaging in discussions with colleagues who have different perspectives can be enriching and help balance your skepticism with practical insights.

    Patient-Centered Care: Uncertainty can remind you to listen to your patients’ experiences and perspectives, which can be as important as clinical knowledge in guiding treatment.

    It’s good to question and explore; it means you’re thoughtful and committed to truly understanding and helping your patients.

  • Unintended Outcomes After FDA Pediatric Antidepressant Warnings

    Unintended Outcomes After FDA Pediatric Antidepressant Warnings

    The article “Intended and Unintended Outcomes After FDA Pediatric Antidepressant Warnings: A Systematic Review” examines the effects of the FDA’s 2003-2004 black box warning on antidepressants regarding the risk of increased suicidal thoughts and behaviors in children and adolescents.

    Intended Outcome:

    • The FDA issued the warning to ensure greater awareness of potential risks, encouraging careful monitoring of pediatric patients taking antidepressants.
    • The goal was to reduce suicidal behaviors potentially linked to antidepressant use in younger populations.

    Unintended Outcomes:

    • The warning led to a significant drop in antidepressant prescriptions for children and adolescents.
    • There was a corresponding increase in untreated depression, which may have led to higher rates of suicide attempts and worsening mental health outcomes in some cases.
    • Reduced prescriptions were associated with a decrease in diagnosis and treatment of mood disorders in pediatric populations.
    • The warning inadvertently caused confusion among healthcare providers and parents, often resulting in delays in seeking treatment for depression or anxiety.

    Post-Warning Trends:

    • Follow-up research found no consistent evidence that the use of antidepressants in pediatric patients increases the risk of completed suicides.
    • The decline in antidepressant use and increase in suicidal behaviors during the period following the warning suggest unintended negative consequences of the FDA’s decision.

    Conclusions:

    • While the warning achieved its goal of raising awareness about the risks of antidepressants in children, it also resulted in under-treatment of depression, potentially exacerbating mental health challenges.
    • The article calls for balanced decision-making in pediatric antidepressant use, emphasizing the need for risk-benefit assessments and careful monitoring rather than outright avoidance of antidepressants.

      The FDA’s black box warning led to a reduction in antidepressant use but also to increased untreated mental illness, highlighting the complexities of addressing medication risks in vulnerable populations.

    1. Antidepressants and the Black Box Warning: Has Treatment Declined?

      Antidepressants and the Black Box Warning: Has Treatment Declined?

      The FDA’s black box warning on antidepressants highlights an increased risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults during the early stages of treatment. However, while this warning raised concerns, it’s essential to understand its context:

      • The Risk: Antidepressants, especially SSRIs, can cause agitation or mood swings during the first few weeks of use, which may increase the risk of suicidal ideation. But studies have shown that untreated depression carries a far greater risk of suicide.
      • Impact on Treatment: Initially, the warning led to a reduction in prescriptions, especially for younger populations. However, there is now growing recognition that avoiding treatment for depression and anxiety can lead to worsened outcomes, including a higher risk of suicide.
      • Guidance: The black box warning does not mean antidepressants are dangerous for everyone. It is a reminder that careful monitoring during the first few weeks of treatment is essential. Psychotherapy combined with medication remains the most effective treatment for many.

      The takeaway: Antidepressants save lives, but starting treatment should always involve open communication between the patient and healthcare provider to manage risks and monitor progress closely.